The multiomics market in the United States is expected to reach a projected revenue of US$ 4,363.0 million by 2033. A compound annual growth rate of 15.6% is expected of the United States multiomics market from 2026 to 2033.
In terms of revenue, U.S. accounted for 43.7% of the global multiomics market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In North America, U.S. multiomics market is projected to lead the regional market in terms of revenue in 2033.
Canada is the fastest growing regional market in North America and is projected to reach USD 430.5 million by 2033.
The multiomics market in the U.S. is highly competitive due to the growing demand for comprehensive biological insights fueled by advancements in omics technologies. This competition is intensified by active R&D efforts in academia and industry, with institutions and companies vying for funding and breakthrough discoveries.
For instance, in 2023, the Keck School of Medicine at the University of Southern California (USC) secured a significant 5-year, USD 50.3 million research grant from the National Institutes of Health (NIH).
This funding will support a multiomics study conducted by a consortium of six sites, with a primary focus on investigating various health conditions, including fatty liver disease, hepatocellular carcinoma, chronic kidney disease, and asthma.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Multiomics Market Outlook will help companies and investors design strategic landscapes.
Bulk Multiomics was the largest segment with a revenue share of 82.92% in 2025.
Horizon Databook has segmented the U.S. multiomics market based on single-cell multiomics, bulk multiomics covering the revenue growth of each sub-segment from 2021 to 2033.
The multiomics market in the U.S. is highly competitive due to the growing demand for comprehensive biological insights fueled by advancements in omics technologies. This competition is intensified by active R&D efforts in academia and industry, with institutions and companies vying for funding and breakthrough discoveries.
For instance, in 2023, the Keck School of Medicine at the University of Southern California (USC) secured a significant 5-year, USD 50.3 million research grant from the National Institutes of Health (NIH).
This funding will support a multiomics study conducted by a consortium of six sites, with a primary focus on investigating various health conditions, including fatty liver disease, hepatocellular carcinoma, chronic kidney disease, and asthma.
U.S. Multiomics Market Type Outlook (Revenue, USD Million , 2021-2033)
Single-cell Multiomics
Bulk Multiomics
U.S. Multiomics Market Platform Outlook (Revenue, USD Million , 2021-2033)
Genomics
Transcriptomics
Proteomics
Metabolomics
Integrated Omics Platforms
U.S. Multiomics Market Product & Service Outlook (Revenue, USD Million , 2021-2033)
Services
Product
U.S. Multiomics Market End Use Outlook (Revenue, USD Million , 2021-2033)
Pharmaceutical & Biotechnology Companies
Others
Academic & Research Institutes
U.S. Multiomics Market Application Outlook (Revenue, USD Million , 2021-2033)
Immunology
Cell Biology
Oncology
Neurology
Reasons to subscribe to Multiomics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Multiomics Market Outlook databook
Our clientele includes a mix of Multiomics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Multiomics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Multiomics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.